View Item 

Show simple item record

Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?
dc.contributor.authorHeidelbaugh, J. J.en_US
dc.contributor.authorMetz, D. C.en_US
dc.contributor.authorYang, Y.‐x.en_US
dc.date.accessioned2012-07-12T17:23:05Z
dc.date.available2013-08-01T14:04:39Zen_US
dc.date.issued2012-06en_US
dc.identifier.citationHeidelbaugh, J. J.; Metz, D. C.; Yang, Y.‐x. (2012). "Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?." International Journal of Clinical Practice 66(6). <http://hdl.handle.net/2027.42/92027>en_US
dc.identifier.issn1368-5031en_US
dc.identifier.issn1742-1241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/92027
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titleProton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Family Medicine, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDivision of Gastroenterology and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAen_US
dc.contributor.affiliationotherDivision of Gastroenterology, GI Physiology Laboratory, Acid Peptic Disorders Specialty Program, Digestive and Liver Center, Perelman School of Medicine, University of Pennsylvania, University of Pennsylvania Hospital, Philadelphia, PA, USAen_US
dc.identifier.pmid22607510en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/92027/1/j.1742-1241.2012.02921.x.pdf
dc.identifier.doi10.1111/j.1742-1241.2012.02921.xen_US
dc.identifier.sourceInternational Journal of Clinical Practiceen_US
dc.identifier.citedreferencede VriesF, Cooper AL, Cockle SM et al. Fracture risk in patients receiving acid‐suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20: 1989 – 98.en_US
dc.identifier.citedreferenceGray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 2011; 170: 765 – 71.en_US
dc.identifier.citedreferenceCorley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine‐2 receptor antagonists are associated with hip fractures among at‐risk patients. Gastroenterology 2010; 139: 93 – 101.en_US
dc.identifier.citedreferenceKaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951 – 9.en_US
dc.identifier.citedreferenceYang Y‐X, Lewis JD, Epstein S et al. Long‐term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947 – 53.en_US
dc.identifier.citedreferenceVestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76 – 83.en_US
dc.identifier.citedreferenceTargownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis‐related fractures. CMAJ 2008; 179: 319 – 26.en_US
dc.identifier.citedreferenceTargownik LE, Lix LM, Leung S et al. Proton‐pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896 – 904.en_US
dc.identifier.citedreferenceDial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital impatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ 2004; 171: 33 – 8.en_US
dc.identifier.citedreferenceDial S, Delaney JAC, Barkun AN et al. Use of gastric acid‐suppressive agents and the risk of community‐acquired Clostridium difficile ‐associated disease. JAMA 2005; 294: 2989 – 95.en_US
dc.identifier.citedreferenceDial S, Delaney JAC, Schneider V et al. Proton pump inhibitor use and risk of community‐acquired Clostridium difficile ‐associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175: 745 – 8.en_US
dc.identifier.citedreferenceYearsley KA, Gilby LJ, Ramadas AV et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile ‐associated diarrhea. Aliment Pharmacol Ther 2006; 24: 613 – 9.en_US
dc.identifier.citedreferenceLeonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047 – 56.en_US
dc.identifier.citedreferenceJayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five‐year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Cli Lab Sci 2007; 37: 241 – 7.en_US
dc.identifier.citedreferenceAseeri M, Schroeder T, Kramer J et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium‐difficile ‐associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103: 2308 – 13.en_US
dc.identifier.citedreferenceGilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. The randomized, double‐blind OCLA (Omeprazole CLopidogrel Aspirin) Study. J Am Coll Cardiol 2008; 51: 256 – 60.en_US
dc.identifier.citedreferenceSiller‐Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.en_US
dc.identifier.citedreferenceSmall DS, Farid NA, Payne CD et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasurgel and clopidogrel. J Clin Pharmacol 2008; 48: 475 – 84.en_US
dc.identifier.citedreferenceRay S, Delaney M, Muller AF. Proton pump inhibitors and acute interstitial nephritis. BMJ 2010; 341: 668 – 70.en_US
dc.identifier.citedreferenceDrug Topics, Pharmacy Facts and Figures. http://drugtopics.modernmedicine.com/drugtopics/article/articleList.jsp?categoryId=7604 (accessed August 2011)en_US
dc.identifier.citedreferenceKahrilas PJ, Shaheen NJ, Vaezi MF et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383 – 91.en_US
dc.identifier.citedreferenceDeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190 – 200.en_US
dc.identifier.citedreferenceMetz DC, Yang YX. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115 – 27.en_US
dc.identifier.citedreferenceSchubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134: 1842 – 60.en_US
dc.identifier.citedreferenceSachs G, Shin JM, Howden CW. The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23 ( suppl ): 2 – 8.en_US
dc.identifier.citedreferenceFendrick AM, Shaw M, Schachtel B et al. Self‐selection and use patterns of over‐the‐counter omeprazole for frequent heartburn. Clin Gastroenterol Hepatol 2004; 2: 17 – 21.en_US
dc.identifier.citedreferenceShi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008; 64: 935 – 51.en_US
dc.identifier.citedreferenceMetz DC, Strader DB, Orbuch M et al. Use of omeprazole in Zollinger‐Ellison syndrome: a prospective nine year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597 – 610.en_US
dc.identifier.citedreferenceKahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterol 2008; 135: 1392 – 413.en_US
dc.identifier.citedreferenceScheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 32: 667 – 77.en_US
dc.identifier.citedreferenceConrad SA, Gabrielli A, Margolis B et al. Randomized, double‐blind comparison of immediate‐release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33: 760 – 5.en_US
dc.identifier.citedreferenceAmerican Society of Health‐System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health-Syst Pharm 1999; 56: 347 – 79.en_US
dc.identifier.citedreferenceKlinkenberg‐Knol EC, Nelis F, Dent J et al. Long‐Term Study Group. Long‐term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661 – 9.en_US
dc.identifier.citedreferenceKlinkenberg‐Knol EC, Jansen JB, Lamers CB et al. Temporary cessation of long‐term maintenance treatment with omeprazole in patients with H2‐receptor‐antagonist‐resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output. Scand J Gastroenterol 1990; 11: 1144 – 50.en_US
dc.identifier.citedreferenceWaldum HL, Arnestad JS, Brenna E et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649 – 53.en_US
dc.identifier.citedreferenceHunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007; 25: 39 – 46.en_US
dc.identifier.citedreferenceInadomi JM, Jamal R, Murata GH et al. Step‐down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095 – 100.en_US
dc.identifier.citedreferenceInadomi JM, McIntyre L, Bernard L et al. Step‐down from multiple‐ to single‐dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98: 1940 – 4.en_US
dc.identifier.citedreferenceReimer C, Søndergaard B, Hilsted L et al. Proton‐pump inhibitor therapy induces acid‐related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80 – 7.en_US
dc.identifier.citedreferenceNiklasson A, Lindström L, Simrén M et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double‐blind placebo‐controlled trial. Am J Gastroenterol 2010; 105: 1531 – 7.en_US
dc.identifier.citedreferenceMetz DC, Pilmer BL, Han C et al. Lack of acid and symptom rebound after withdrawal of 4 to 8 weeks of dexlansoprazole MR or lansoprazole therapy. Am J Gastroenterol 2009; 29: 742 – 54.en_US
dc.identifier.citedreferenceMetz DC, Howden CW, Perez MC et al. Dexlansoprazole MR, a proton pump inhibitor with dual delayed‐release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009; 29: 742 – 54.en_US
dc.identifier.citedreferenceHowden CW, Larsen LM, Perez MC et al. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009; 30: 895 – 907.en_US
dc.identifier.citedreferencePisegna JR, Norton JA, Slimak GG et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger‐Ellison syndrome. Gastroenterology 1992; 102: 767 – 78.en_US
dc.identifier.citedreferenceForgacs I, Loganayagam A. Overprescribing proton pump inhibitors is expensive and not evidence based. BMJ 2008; 336: 2 – 3.en_US
dc.identifier.citedreferenceNaunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25: 333 – 40.en_US
dc.identifier.citedreferenceBatuwitage B, Kingham JCG, Morgan NE et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83: 66 – 8.en_US
dc.identifier.citedreferenceMat Saad AZ, Collins N, Lobo MM et al. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005; 59: 31 – 4.en_US
dc.identifier.citedreferenceHeidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic impact of overutilization of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010; 16: e228 – 34.en_US
dc.identifier.citedreferenceJacobson BC, Ferris TG, Shea TL et al. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003; 98: 51 – 8.en_US
dc.identifier.citedreferenceInadomi JM, Fendrick AM. PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol 2005; 3: 208 – 15.en_US
dc.identifier.citedreferenceHeidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non‐intensive care unit hospitalized patients. Am J Gastroenterol 2006; 101: 2200 – 5.en_US
dc.identifier.citedreferenceNardino RJ, Vender RJ, Herbert PN. Overuse of acid‐suppressive therapy in hospitalized patients. Am J Gastroenterol 2000; 95: 3118 – 22.en_US
dc.identifier.citedreferenceZink DA, Pohlman M, Barnes M, Cannon ME. Long‐term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005; 21: 1203 – 9.en_US
dc.identifier.citedreferenceCash BD. Evidence‐based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med 2002; 30 ( Suppl. 6 ): S373 – 8.en_US
dc.identifier.citedreferenceHeidelbaugh JJ, Goldberg KL, Inadomi JM. Adverse risks associated with proton pump inhibitors: a systematic review. Gastroenterol Hepatol 2009; 5: 725 – 34.en_US
dc.identifier.citedreferenceSarkar M, Hennessy S, Yang Y‐X. Proton‐pump inhibitor use and the risk for community‐acquired pneumonia. Ann Int Med 2008; 149: 391 – 8.en_US
dc.identifier.citedreferenceYang YX, Metz DC. Peptic ulcer disease: diagnosis and management. In: Al‐Kawas F, ed. Gastrointestinal Diseases: An Endoscopic Approach. 2nd edn. USA: SLACK Incorporated, 2002: 385 – 410.en_US
dc.identifier.citedreferenceMetz D. Proton pump inhibitor therapy: safety issues. In: Howden CW, ed. Advances in Digestive Disease. Bethesda, MD: AGA Institute press, 2007: 3 – 14.en_US
dc.identifier.citedreferenceShin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Reports 2008; 10: 528 – 34.en_US
dc.identifier.citedreferenceFDA Drug Safety Communication: Low Magnesium Levels can be Associated with Long‐Term use of Proton Pump Inhibitor Drugs (PPIs), Vol. 2011. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm (accessed 28 March 2012)en_US
dc.identifier.citedreferenceBhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909 – 17.en_US
dc.identifier.citedreferenceGillen D, Wirz AA, Ardill JE et al. Rebound hypersecretion after omeprazole and its relation to on‐treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239 – 47.en_US
dc.identifier.citedreferenceGillen D, Wirz AA, McColl KEL. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. [Erratum appears in Gastroenterol 2004;127(2):694]. Gastroenterology 2004; 126: 980 – 8.en_US
dc.identifier.citedreferenceYang YX, Hennessy S, Propert K et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748 – 54.en_US
dc.identifier.citedreferenceVan Soest EM, Van Rossum LGM, Dieleman JP et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103: 966 – 73.en_US
dc.identifier.citedreferenceRobertson DJ, Larsson H, Friis S et al. Proton pump inhibitor use and risk of colorectal cancer: a population‐based, case–control study. Gastroenterology 2007; 133: 755 – 60.en_US
dc.identifier.citedreferenceLaheij RJF, Sturkenboom MCJM, Hassing R‐J et al. Risk of community‐acquired pneumonia and use of gastric acid‐suppressive drugs. JAMA 2004; 292: 1955 – 60.en_US
dc.identifier.citedreferenceGulmez SE, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community‐acquired pneumonia: a population‐based case–control study. Arch Int Med 2007; 167: 950 – 5.en_US
dc.identifier.citedreferenceChiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population‐based case–control study. Pharmacoepidemiol Drug Saf 2010; 19: 1131 – 6.en_US
dc.identifier.citedreferencePouwels S, Lalmohamed A, Souverein P et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population‐based case–control study. Osteoporos Int 2011; 22: 903 – 10.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1742-1241.2012.02921.x.pdf
Size:
291.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.